Reishi : le guide de référence

Résumé PubMed complet

Myocardial ischemic injury is characterized by impaired energy metabolism and oxidative stress, which contribute to cardiac dysfunction and disease progression. Ganoderma lucidum polysaccharide (GLP), a major bioactive component of Ganoderma lucidum, exhibits various pharmacological activities; however, its protective effects against myocardial ischemic injury and underlying mechanisms remain unclear. This study investigated the effects of GLP against isoproterenol (ISO)-induced myocardial ischemic injury and its involvement in metabolic regulation and oxidative stress. A mouse myocardial ischemic injury model was established by subcutaneous injection of ISO (2 mg/kg/day) for 11days. Mice were randomly divided into normal control, model, GLP treatment groups with GLP administered orally at 50 and 100 mg/kg/day, and at 50 mg/kg/day by intraperitoneal injection. An ISO-induced injury model in vitro was established using AC16 cardiomyocytes, which were pretreated with GLP (0.25 ~ 1.00 µg/mL) followed by ISO exposure (40 µM, 24 h). GLP significantly alleviated ISO-induced myocardial injury, reduced cardiac hypertrophy, improved histopathological alterations, and decreased serum AST and LDH activities in mice. Similar protective effects were observed in AC16 cells. Moreover, GLP restored myocardial energy metabolic homeostasis, by improving ATP, phosphocreatine, creatine, and total adenine nucleotides levels, while reducing cAMP accumulation. GLP also alleviated oxidative stress by decreasing malondialdehyde level and enhancing total superoxide dismutase activity. Furthermore, GLP increased the expression of AMPK-α2, phosphorylated AMPK-α2, PGC-1α, and PPAR-α in myocardial tissue. These findings suggest that GLP protects against ISO-induced myocardial ischemic injury by improving myocardial energy metabolism and reducing oxidative stress, with AMPK/PGC-1α/PPAR-α-related metabolic regulation potentially contributing to its cardioprotective effects.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Zhang XT, Hu MQ, Wu SY, Feng JY, Xu X, Gan ZY, Gao JP
Revue : Journal of natural medicines
Publication : 2026-10-05 · PMID 42830376 · DOI 10.1007/s11418-026-02093-8

Résumé PubMed complet

Nitrogen metabolism is fundamental to fungal growth, development, and the biosynthesis of bioactive metabolites. The GATA transcription factor AreA plays a pivotal regulatory role in nitrogen metabolite repression. While the molecular mechanisms by which AreA responds to nitrogen sources have been relatively well elucidated in ascomycetes, they remain poorly understood in basidiomycetes. Here, using the macrofungus Ganoderma lucidum as a model, we elucidated a molecular mechanism by which an N-acetyltransferase (Nat) influences AreA nuclear entry under non-preferred nitrogen sources, thereby promoting nitrogen catabolic gene expression and the utilization of non-preferred nitrogen sources. Through a yeast two-hybrid library screen, we identified Nat as an AreA-interacting protein, and their physical interaction was subsequently validated by yeast two-hybrid and bimolecular fluorescence complementation (BiFC) assays. In vitro acetylation assays coupled with mass spectrometry analysis demonstrated that Nat specifically acetylates lysine residues 619 and 916 of AreA. In vivo experiments further showed that silencing of nat reduced the acetylation level of AreA. Nitrate conditions induced the expression of nat and increased NAT protein levels, compared with ammonium conditions. Silencing of nat did not affect areA transcription or total AreA protein abundance; however, it significantly reduced nuclear AreA accumulation with a concomitant increase in cytoplasmic retention. Compared with the wild-type strain, nuclear AreA accumulation in the nat-silenced strain was reduced by approximately 70% under nitrate conditions. Consequently, the expression and enzymatic activity of AreA-regulated nitrogen metabolic genes, including glutamine synthetase (gs) and nitrate reductase (nr), were markedly suppressed. This study illuminates a post-translational mechanism by which non-preferred nitrogen sources activate AreA in basidiomycetes. It further reveals a role for protein acetylation in the nitrogen metabolism of G. lucidum, thereby expanding our understanding of nitrogen metabolic networks in fungi.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique in vitro à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude est menée sur des cellules ou en laboratoire. Elle décrit un signal biologique, pas un bénéfice démontré chez l’humain.

Source

Auteurs : Li H, Qiao J, Zhang S, Huang A, Wu K, Ren A, Liu R, Shi L, et al.
Revue : Microbiological research
Publication : 2026-09-29 · PMID 42826594 · DOI 10.1016/j.micres.2026.128745

Résumé PubMed complet

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that causes memory loss, cognitive decline, and ultimately dementia. Available pharmacotherapies mainly provide symptomatic relief and do not adequately address the underlying pathology. Ganoderma lucidum (Curtis) P. Karst (G. lucidum) is a widely used medicinal mushroom rich in bioactive compounds, including polysaccharides, triterpenoids, and proteins. These constituents may alleviate the neuroinflammation and oxidative stress involved in AD pathogenesis. This review critically integrates evidence for the therapeutic effects of G. lucidum on AD-associated neuroinflammation and oxidative stress. It has three aims: (1) to examine how G. lucidum may disrupt the bidirectional vicious cycle between neuroinflammation and oxidative stress; (2) to compare the pharmacological profiles of different preparations and purified constituents; and (3) to evaluate AD-specific barriers to translation and inform future clinical development. We searched PubMed, Web of Science, Google Scholar, and CNKI for studies on G. lucidum and AD through 2026 using combinations of the primary term "Ganoderma lucidum" with "Alzheimer's disease," "neuroinflammation," "oxidative stress," and related terms. Included were original research, mechanism-based studies, and clinical evidence on G. lucidum bioactives in AD or related models. Evidence was stratified by design robustness and presented as a narrative synthesis. The available evidence indicates that G. lucidum may act on several pathological processes associated with AD. Experimental studies report effects on abnormal amyloid-β (Aβ) aggregation, tau hyperphosphorylation, cholinergic dysfunction, neuroinflammation, oxidative stress, and neuronal apoptosis. These findings illustrate the multi-target pharmacology of traditional Chinese medicines and help explain the potential activity of G. lucidum against AD. G. lucidum has anti-inflammatory, antioxidant, and neuroprotective activities that may be relevant to AD management. This review summarizes its reported effects on AD-related neuroinflammation and oxidative stress and examines the underlying mechanisms. Clinical translation remains limited by poor blood-brain barrier (BBB) permeability, uncertain pharmacokinetics, and non-standardized dosing. Rigorous preclinical studies and controlled early-phase trials are therefore required. Addressing these barriers may inform the potential translation of G. lucidum as an adjunctive strategy in multimodal AD therapy. We also identify key evidence gaps and propose a component-specific framework for future research.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme revue de littérature à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Pas directement. Il s’agit d’une synthèse de travaux qui peuvent inclure des données humaines et précliniques. Il faut vérifier les études incluses avant de tirer une conclusion clinique.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette revue rassemble des travaux qui peuvent utiliser des modèles, des doses et des préparations différents. Elle ne remplace pas un essai clinique sur un produit précis.

Source

Auteurs : Gao J, Zhang W, Yang F, Peng G, Zhang T, Dong T, Wang J
Revue : Journal of ethnopharmacology
Publication : 2026-09-29 · PMID 42810460 · DOI 10.1016/j.jep.2026.122442

Résumé PubMed complet

Ganoderma lucidum polysaccharides (GLPs), the core bioactive macromolecules of Ganoderma lucidum, have garnered massive research attention for their robust immunomodulatory effects. Cumulative data verify that GLP β-glucans specifically bind pattern recognition receptor Dectin-1, alongside auxiliary co-receptors for synergistic regulation. Dectin-1 engagement triggers the Syk-CARD9 cascade, promoting NF-κB nuclear translocation to upregulate immune genes and directly regulate macrophage polarization and dendritic cell maturation via Dectin-1, which in turn indirectly activates NK cells and T cells through cytokine release (IL-12, IL-18) and antigen presentation by matured dendritic cells. This review details GLP structural characteristics and corresponding structure-immunomodulation relationships, highlighting the pivotal Dectin-1/NF-κB signaling axis. It summarizes state-of-the-art GLP research in anti-tumor, anti-inflammatory therapy and immune homeostasis, clarifies molecular mechanisms, sorts preclinical outcomes, and addresses obstacles limiting clinical translation. GLPs are classified by raw sources, extraction protocols, molecular weight, monosaccharide components, glycosidic linkages and spatial conformations; each structural trait is paired with dedicated characterization and cell/animal verification assays to eliminate superficial structure-activity generalizations. This work lays theoretical groundwork for fungal polysaccharide immunomodulator preclinical development, yet human clinical trials remain indispensable.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme revue de littérature à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Pas directement. Il s’agit d’une synthèse de travaux qui peuvent inclure des données humaines et précliniques. Il faut vérifier les études incluses avant de tirer une conclusion clinique.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette revue rassemble des travaux qui peuvent utiliser des modèles, des doses et des préparations différents. Elle ne remplace pas un essai clinique sur un produit précis.

Source

Auteurs : Zheng J, Zuo Y, Wang Y, Sun Y, Chen Y, Huang Q, Yu M, Liu C
Revue : International journal of biological macromolecules
Publication : 2026-09-23 · PMID 42777993 · DOI 10.1016/j.ijbiomac.2026.154584

Résumé PubMed complet

The young sprouts pruned to ensure optimal growth of Ganoderma lucidum, called Ganoderma lucidum sprouts (GLS), are often discarded as waste despite being rich in polysaccharides (GLSP). Therefore, an ultrasonic-assisted extraction (UAE) method for GLSP was developed and optimized via entropy weight method-response surface methodology (EWM-RSM) considering yield, activity, and energy consumption with energy consumption treated as a negative indicator. Energy consumption and related greenness metrics were subsequently incorporated into the AGREEprep assessment, which evaluates sample preparation greenness across ten principles. The physicochemical properties, including thermal stability and functional groups, and in vitro activities were characterized. The results showed that the optimal conditions of UAE were as follows: power 280 W, liquid-to-material ratio 38:1 mL/g, ultrasonic time 27.5 min, and temperature 47°C. At this time, the extraction rate was 2.22% and the energy consumption was 0.292 Wh/sample. The AGREEprep evaluation confirmed that this extraction process is environmentally friendly and highly green. UAE had higher purity and better thermal stability compared with microwave-extraction and thermal reflux extraction, along with a yield increase of 24.02% and 47.02%. Infrared spectroscopy analysis further showed that UAE did not change the basic chemical skeleton of the polysaccharide, but there was a significant difference in the pyranose ring peak area. In addition, UAE performed better in terms of ABTS+ radical scavenging activity, hydroxyl radicals, total reducing power and nitrite scavenging activity. This UAE process provides a theoretical foundation and fresh perspectives on the effective extraction of GLSP and the high-value application of GLS.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique in vitro à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude est menée sur des cellules ou en laboratoire. Elle décrit un signal biologique, pas un bénéfice démontré chez l’humain.

Source

Auteurs : Wang Y, Lai Y, Shi K, Chen Q, Li S, Wan P, Zhou H
Revue : Ultrasonics sonochemistry
Publication : 2026-09-23 · PMID 42777379 · DOI 10.1016/j.ultsonch.2026.108077

Résumé PubMed complet

Gemcitabine (GEM), a first-line chemotherapeutic agent, may fail to prevent recurrence in some settings. Traditional Chinese medicine emphasizes Yin-Yang balance and "fuzheng" approaches and may offer complementary strategies. Ganoderma lucidum polysaccharides (GLP) exhibit immune-enhancing activity, but evidence for direct anti-tumor efficacy, either alone or in combination with low-dose GEM, remains limited. Using a murine 4T1 breast cancer model, we integrated flow cytometry, 16S rRNA gene sequencing, and gas chromatography-mass spectrometry to evaluate the anti-tumor activity of GLP combined with low-dose GEM. GLP alone enhanced immune parameters but did not significantly suppress tumor growth, whereas low-dose GEM reduced tumor volume and activated anti-tumor immunity. Notably, the GLP plus GEM combination produced greater tumor inhibition than either treatment alone and was associated with increased IFN-γ and TNF-α levels, enhanced CD8+ T-cell infiltration, and enrichment of Ligilactobacillus, Duncaniella, and Faecalibaculum in the gut microbiota, and elevated serum levels of short-chain fatty acids and tryptophan. Notably, the antitumor effect in the combination group was accompanied by reduced tumoral IDO expression and elevated serum tryptophan, which were statistically correlated; however, as kynurenine levels were not quantified in this study, we cannot attribute this correlation to altered IDO enzymatic activity or establish a direct functional link along the IDO-tryptophan metabolic pathway. Thus, the combination of GLP and low-dose GEM exerts a synergistic anti-tumor effect.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Zhang W, Chen G, Li S, Zhao P, Cheng C, Lu Z, Song Z
Revue : Molecular carcinogenesis
Publication : 2026-09-19 · PMID 42762514 · DOI 10.1002/mc.70178

Résumé PubMed complet

Obesity is a major global public health challenge. A high-fat diet (HFD) is a key contributing factor, closely associated with gut microbiota dysbiosis. Although immunomodulatory effects of Ganoderma lucidum spore oil (GLSO) have been reported, its role in lipid metabolism disorders and its interaction with gut microbiota remain incompletely understood. In this study, an HFD-induced obese mouse model was established and treated with GLSO (800 mg kg-1 day-1) for 82 days. Integrated analyses - including 16S rRNA sequencing, metabolomics, fecal fermentation of GLSO (FGLSO), and HepG2 cell experiments - were performed to evaluate metabolic effects and potential microbiota-related mechanisms. Ganoderma lucidum spore oil significantly reduced body weight gain, fasting blood glucose, serum lipid levels - including total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) - and inflammatory markers, specifically tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6). It also improved gut microbiota composition by increasing microbial diversity and enriching beneficial taxa such as Bacillus and unclassified_Muribaculaceae. These changes were accompanied by increased levels of short-chain fatty acids (SCFAs), particularly acetate and propionate, as well as alterations in bile acid metabolism. Further analysis suggested that metabolites may be associated with the regulation of hepatic lipid metabolism, potentially involving the peroxisome proliferator-activated receptor alpha (PPARα) signaling pathway. Fecal fermentation of GLSO exhibited stronger lipid-lowering effects than native GLSO in vitro, indicating that gut microbiota-mediated biotransformation may enhance the bioactivity of GLSO. Collectively, these findings suggest that GLSO alleviates HFD-induced metabolic disorders and highlight a potential role of gut microbiota in modulating its metabolic effects and enhancing its bioactivity. © 2026 Society of Chemical Industry.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Zhang J, Yang Y, Zhou X, Yang W, Yuan Z, Liu J, Su A, Xie M, et al.
Revue : Journal of the science of food and agriculture
Publication : 2026-09-16 · PMID 42750144 · DOI 10.1002/jsfa.71035

Résumé PubMed complet

Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that, regarding the histological images shown in Fig. 1B on p. 149, the "Ctrl" and "GLPs 5μg/ml" data panels contained an overlapping section of data, suggesting that these data panels were derived from the same original source where different experimental conditions were reported. In addition, a concern was raised regarding the antibody that had been used to probe for p21 in the western blot experiments in Fig. 5 (cat. no. sc‑136020, purchased from Santa Cruz Biotechnology, Inc.), since apparently this antibody is specific for a different protein, sometimes referred to as p21‑ARC, which is related to the actin cytoskeleton. The authors have been contacted by the Editorial Office to offer an explanation for these apparent anomalies in the presentation of the data in their paper, and we are awaiting their response. Due to the fact that we have been made aware of potential issues surrounding the scientific integrity of this paper, we are issuing an Expression of Concern to notify readers of this potential problem while the Editorial Office continues to investigate this matter further. [Molecular Medicine Reports 17: 147‑157, 2018; DOI: 10.3892/mmr.2017.7904].

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude de recherche à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

La portée de cette publication dépend du modèle, de la préparation, de la dose et des critères étudiés. Le résumé PubMed permet d’en vérifier le contexte exact.

Source

Auteurs : Zhao X, Zhou D, Liu Y, Li C, Zhao X, Li Y, Li W
Revue : Molecular medicine reports
Publication : 2026-09-11 · PMID 42725400 · DOI 10.3892/mmr.2026.14010